|
Total income stood at Rs 1,859 crore in Q1 FY24, down 20.7% from Rs 2,343 crore recorded in the same period a year ago.
Forex gain for the current quarter amounted to Rs 3 crore as against a gain of Rs 56 crore during the corresponding quarter of the last year.
Consolidated profit before tax dropped 42.25% to Rs 492 crore in the quarter ended 30 June 2023 as compared to Rs 852 crore posted in Q1 FY23.
Total expense decreased 8.32% year on year to Rs 1,367 crore in Q1 FY24. Cost of material consumed was at Rs 829 crore (up 6.42% YoY), employee benefit expenses stood at Rs 263 crore (up 6.91% YoY) and other expenses stood at Rs 323 crore (down 7.45% YoY) during the period under review.
On a standalone basis, the company net profit tumbled 50.07% to Rs 345 crore on 21.09% fall in total revenue to Rs 1,810 crore in Q1 FY24 over Q1 FY23.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
|